SEC Form 4 · accession 0001209191-15-036112

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Apr 22, 2015

Accepted (ET)

Apr 24, 2015 · 4:45 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Apr 22, 2015	M	1,300	$17.16	A	387,584	D
Common Stock	Apr 22, 2015	M	10,400	$35.64	A	397,984	D
Common Stock^F2,F3	Apr 22, 2015	S	2,173	$131.41	D	395,811	D
Common Stock^F3,F4	Apr 22, 2015	S	5,427	$132.22	D	390,384	D
Common Stock^F3,F5	Apr 22, 2015	S	4,100	$133.32	D	386,284	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock^F6	holding	—	—		—	122,700	I	Common Stock held in trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F7	$17.16	Apr 22, 2015	M	1,300	D	—	Jul 19, 2015	Common Stock	1,300	16,100	D
Stock Option (right to buy)^F7	$35.64	Apr 22, 2015	M	10,400	D	—	Feb 1, 2016	Common Stock	10,400	416,800	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Open market sales reported on this line occurred at a weighted average price of $131.41 (range $130.82 to $131.81).
F3Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4Open market sales reported on this line occurred at a weighted average price of $132.22 (range $131.82 to $132.80).
F5Open market sales reported on this line occurred at a weighted average price of $133.32 (range $132.95 to $133.63).
F6Common stock held in grantor retained annuity trusts.
F7Fully vested.